|Title:||Methods for treating HCV|
|Abstract:|| The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.|
|Inventor(s):|| Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Lincolnshire, IL), Cohen; Daniel E. (Wilmette, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL), Podsadecki; Thomas J. (Northbrook, IL) |
|Assignee:|| AbbVie Inc. (North Chicago, IL) |
|Filing Date:||Dec 23, 2013|
|Claims:||1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to a patient infected with HCV genotype 1, wherein said treatment lasts for 8 or 12 weeks and does not include administration of interferon to said patient, wherein said at least two DAAs comprise Compound 1 ##STR00010## Compound 4 ##STR00011## and PSI-7977, and wherein Compound 1 is administered with ritonavir. |
2. The method of claim 1, wherein said patient is a treatment-naive patient.